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PreviewsGiven the existence of multiple Smo-inde-
pendent mechanisms of Hh pathway acti-
vation, such as gene amplification or
increased activity of the Gli transcription
factors as well as inactivation of the
intracellular repressor Sufu, inhibition
of Gli transcriptional effectors appears
appealing. Of relevance, activation of the
S6K1 kinase in the PI3K/mTOR pathway
has recently been shown to increase
active GLI1 levels (Wang et al., 2012),
which may contribute to the observed
Smo inhibitor resistance caused by
increased PI3K/mTOR signaling.
A concern with regard to the clinical use
of Smo inhibitors is side-effects such as
weight loss and muscle cramping that
have no known connection to canonical
Hh-signaling. Smo-dependent activation
of AMPK and Ca2+ influx in brown fat
and muscle cells elicited by several Smo
inhibitors is now proposed as an under-
lying mechanism (Teperino et al., 2012).Investigation of the presence or absence
of such activity induced by itraconazole
is therefore warranted.
The findings by Kim et al. (2013) are,
despite unanswered questions, very en-
couraging in that they suggest immedi-
ately available second-line treatment
options for Smo inhibitor-resistant tumors
to be evaluated in the clinical setting.
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In this issue of Cancer Cell, Liang and colleagues demonstrated that sphingosine kinase 1, the enzyme that
catalyzes formation of the biologically active lipid sphingosine 1-phosphate, drives a malicious amplification
loop involving sphingosine 1-phosphate receptor 1 and the NF-kB/IL-6/STAT3 pathway. This appears critical
for progression from chronic inflammation to colon cancer.There is substantial evidence linking
inflammatory bowel disease, particularly
ulcerative colitis (UC), with colon cancer,
termed colitis-associated cancer (CAC).
In this regard, mucosal inflammatory cell
types can promote (regulatory T cells
[Tregs], type 2 macrophages, CD4+ T
helper [Th-17 cells]) or inhibit (CD8+
T cells, natural killer cells) CAC (Monte-
leone et al., 2012). The regulatory effects
of inflammatory cells on the growth and
survival of cancer cells is dependent on
cytokines that can act directly or indi-rectly on these cells. For instance, cyto-
kines such as interleukin-6 (IL-6) and
tumor necrosis factor-alpha (TNF-a)
provide a supportive tumor microenviron-
ment by activating the transcription
factors NF-kB and STAT3, and these are
involved in the development of CAC. Acti-
vation of NF-kB in a tumor microenviron-
ment is associated with enhanced inflam-
mation and release of IL-6, which
promotes CAC (Monteleone et al., 2012).
In this issue of Cancer Cell, Liang
et al. (2013) elegantly demonstrate thatthe sphingosine 1-phosphate receptor 1
(S1PR1) and sphingosine kinase 1
(SphK1), the enzyme that catalyzes the
formation of sphingosine 1-phosphate
(S1P, the natural ligand of S1PR1), are
a missing link between chronic inflamma-
tion and CAC. Indeed, there is sub-
stantial evidence for a role of SphK1 and
S1P in cancer (Pyne and Pyne, 2010).
There were two important findings that
preceded the current study. First, Kawa-
mori et al. (2009) demonstrated that
Sphk1 knockout mice exhibit reduced23, January 14, 2013 ª2013 Elsevier Inc. 5
Figure 1. Schematic Showing how SphK1 and S1P Promote the
NF-kB/IL-6/STAT3/S1PR1 Amplification Loop that Drives Colitis
and CAC
FTY720 ablates colitis and CAC through inhibition and downregulation of
SphK1. The S1P / S1PR1 / NF-kB connection is represented as W146
ablates S1P-stimulated NF-kB activation in naive Sphk2/ mice. The
possible S1P/ S1PR1/ STAT3/ IL-6 connection is represented as Lee
et al. (2010) demonstrated that overexpressing S1PR1 increased IL-6 forma-
tion in MB49 bladder cancer cells, and this was eliminated in Stat3/ mice.
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and tumor development in
a CAC model. Second, Lee
et al. (2010) demonstrated
that STAT3 induces the upre-
gulation of S1PR1, which
reciprocally activates STAT3,
resulting in persistent IL-6
formation to drive tumor
growth and metastasis in
B16 melanoma and MB49
bladder cancer models. The
advance made by Liang et al.
(2013) is the demonstration
that the NF-kB/IL-6/STAT3/
S1PR1 amplification loop is
functional in both colitis and
CAC adenomas and is driven
by SphK1, which is upregu-
lated in UC (Snider et al.,
2009). Moreover, Liang et al.
(2013) were able to ablate
this amplification loop in bothcolitis and CAC using the SphK1 inhibitor
FTY720.
Liang et al. (2013) found that when mice
deficient of SphK2 (the second SphK
isoform) were injected with colontropic
mutagen azooxymethane followed by
oral administration of dextran sodium
sulfate (DSS), there was a marked
increase in tumor number, size, load,
and Ki-67 staining compared with wild-
type (WT) mice. Indeed, there was
a similar increase in intestinal inflamma-
tion in response to DSS compared with
WT mice. Significantly, deletion of Sphk2
was associated with a marked increase
in SphK1 expression, which was shown
to be due to the loss of a SphK2-mediated
inhibition of HDAC1/2, leading to in-
creased expression of c-Jun, a compo-
nent of AP-1 that regulates SphK1
expression. The authors therefore con-
cluded that the enhancing effect of
Sphk2 knockout on colitis and CAC might
be due to the increase in expression of
SphK1. Constitutive NF-kB activation,
nuclear phosphorylated STAT3, elevated
S1PR1 expression, and IL-6/TNF-a
formation were increased in Sphk2/
mice and further enhanced during colitis
development. The role of ‘‘inside-out’’
signaling involving SphK1/S1P/S1PR1 in
colitis was confirmed using either the
SphK1 inhibitor BML-258 (SK1-I) or a
competitive antagonist of S1PR1, W146,
indicating a requirement for S1P forma-
tion and subsequent activation of S1PR16 Cancer Cell 23, January 14, 2013 ª2013 Elrather than constitutive activation of
this receptor. Similarly, the amplification
loop appears operative in naive Sphk2/
mice where W146 reduced activation of
NF-kB and STAT3.
Importantly, reciprocal bone marrow
chimeric mice, generated by the adoptive
transfer of bone marrow into lethally irra-
diated recipients, were used to demon-
strate that hematopoietic cells rather
than intestinal epithelial cells (IECs) drive
NF-kB/IL-6 and STAT3 activation and
colitis and that the principal cells involved
are macrophages, probably of the M1
phenotype. Colitis is then directly linked
with CAC, with the demonstration that
late phase CAC involves infiltration of
macrophages and T cells in the adenoma
leukocyte infiltrates of DSS-challenged
Sphk2/ mice.
FTY720 has been marketed for the
treatment of multiple sclerosis (MS) and
is a functional antagonist of S1PR1
(Brinkmann et al., 2010). FTY720 is con-
verted to FTY720 phosphate by SphK2,
which subsequently binds to S1PR1 on
T cells to induce its downregulation,
thereby preventing egress of T cells
from lymph nodes. This mechanism of
action of FTY720 phosphate is thought
to underlie its therapeutic utility in MS.
Liang et al. (2013) demonstrated that
daily treatment with FTY720 reduced
colitis in WT and Sphk2/ mice. More-
over, FTY720 induced lymphopenia in
Sphk2/ mice, and it was proposedsevier Inc.that FTY720 can be phos-
phorylated by SphK1 albeit
as a poor substrate. Non-
phosphorylated FTY720 is a
competitive inhibitor (with
sphingosine) of SphK1 (To-
nelli et al., 2010), and its
binding site on SphK1 prob-
ably overlaps the catalytic
site of SphK1 so that it might
serve as a substrate while in-
hibiting phosphorylation of
sphingosine.
FTY720 also has anti-
cancer activity in vivo (Pyne
and Pyne, 2010) and inhibits
the S1PR1 activation of
STAT3 in activated B cell-like
diffuse large B cell lymphoma
(Liu et al., 2012). Moreover,
non-phosphorylated FTY720
induces the ubiquitin-protea-
somal degradation of SphK1(Tonelli et al., 2010). Indeed, the proteaso-
mal degradation of SphK1 might explain
how FTY720 reduces the increase in
SphK1 expression in the inflamed colon
of WT mice induced by DSS treatment,
as well as dramatically decreasing
SphK1 expression in Sphk2/ mice.
This effect of FTY720 is likely to be tempo-
rally separated from its use as a substrate
by SphK1 and as a catalytic inhibitor of
S1P formation. Liang et al. (2013) also
demonstrated that FTY720 abrogated
the SphK1/S1P/S1PR1 feed-forward
loop that leads to persistent NF-kB and
STAT3 activation, IL-6 production, and
macrophage recruitment in colitis. In
addition, FTY720 reduced tumor size,
multiplicity, and load in WT and Sphk2/
mice, and administration at late stage
CAC induction was effective in reducing
the proliferation rate in WT mice. This
was also associated with a reduced level
of nuclear phosphorylated STAT3, which
regulates proliferation and IL-6 produc-
tion, while NF-kB activation was reduced
in IECs of CAC adenomas from Sphk2/
mice. Moreover, late FTY720 administra-
tion reduced elevated SphK1 and S1PR1
expression in CAC adenomas and in
distal IECs of the Sphk2/ mice. There-
fore, FTY720 was effective in ablating
activation of NF-kB and STAT3 and
reducing IL-6 levels even in established
tumors.
The link between SphK1/S1P/S1PR1
and NF-kB/IL-6 and STAT3 activation
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Previewsmight represent the Achilles heel of CAC.
Therefore, targeting this amplification
loop with FTY720 or FTY720-based
SphK1 inhibitors might offer the pro-
spect of being able to halt progression
of colitis to colon cancer. There is a strong
possibility that SphK1 provides a pro-
liferative and survival advantage to CAC
cells that enables their clonal expansion
through activation of STAT3 and NF-kB.
In addition, Deng et al. (2012) have shown
that the S1PR1/STAT3 amplification loop
leads to pre-metastatic niche formation,
which has important implications in terms
of targeting SphK1 and S1PR1 to prevent
metastasis. Therefore, understanding the
molecular mechanisms for the deregula-
tion of SphK1 in colitis and CAC seems
a pre-eminent consideration for future
research.
The current findings presented by Liang
et al. (2013) represent a major advance inthe area of CAC. Significantly, the identifi-
cation of the NF-kB/IL-6/STAT3/S1PR1
amplification loop driven by SphK1
(Figure 1) provides a viable target for inter-
vention in colitis to prevent transition to
CAC. This might represent a particularly
innovative approach as chemothera-
peutic resistance is less problematic in
inflammatory cells compared with
tumors.REFERENCES
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